Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) is a development stage life sciences company developing a single-molecule proteome analysis platform, and the news surrounding NAUT often centers on progress toward validating and deploying this technology. The company’s communications highlight its Iterative Mapping method, tau proteoforms assay, and collaborations with leading research institutions as key themes in its news flow.
Readers following Nautilus news can expect updates on platform development milestones, such as the successful installation and testing of the first external field evaluation unit at the Buck Institute for Research on Aging. News has described how researchers at the Buck Institute generated highly reproducible tau proteoform data from neurodegenerative disease samples and used the Nautilus Proteome Analysis Platform to explore region-specific proteoform patterns associated with disease progression.
NAUT news also covers agreements and collaborations, including an agreement with the Allen Institute focused on investigating the connection between tau protein and neurodegenerative conditions such as Alzheimer’s disease. These announcements often discuss efforts to identify novel tau proteoforms, quantify their prevalence, and characterize phosphorylation patterns that may help explain disease course.
Financial results and corporate updates are another important category of Nautilus news. The company regularly issues quarterly earnings press releases describing operating expenses, net loss, cash, cash equivalents, and investments, along with commentary on development progress and plans for its platform and Early Access Program. Investors can also find notices about upcoming earnings calls, participation in healthcare and investor conferences, and regulatory filings reported via Form 8-K.
In addition, Nautilus has announced an Early Access Program for its proteomics platform, starting with a tau proteoforms assay, which is a recurring topic in its news. These articles explain how selected researchers gain access to the Iterative Mapping method, receive support for data interpretation and analysis, and participate in custom assay development partnerships. For anyone tracking NAUT, this news page provides a centralized view of technology, collaboration, commercialization, and financial developments related to the company’s single-molecule proteomics efforts.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its fourth quarter and fiscal year 2021 results, highlighting key achievements and financial metrics. The company completed a business combination with ARYA Sciences Acquisition Corp III, generating approximately $345.5 million. Operating expenses soared 221% to $50.5 million, while net loss widened to $50.3 million from $15.6 million year-over-year. Nautilus announced collaborations with Amgen and MD Anderson, and a strategic partnership with Abcam. As of December 31, 2021, cash and investments totaled $362.1 million, supporting ongoing development.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will participate virtually in the 42nd Annual Cowen Health Care Conference on March 7th, 2022. The presentation is scheduled for 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties can access the live and archived webcast through Nautilus’ website.
Headquartered in Seattle, Nautilus is focused on developing a cutting-edge platform for detailed protein analysis, aiming to advance the field of proteomics and its applications in human health and medicine.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its financial results for Q4 and the full year 2021 before the market opens on February 24, 2022. The company's management will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss these results along with updates on business developments and future outlook. Audio of the webcast will be accessible in the 'Investors' section of the Nautilus website.
Nautilus is focused on developing a single-molecule protein analysis platform aimed at advancing proteomics and improving healthcare.
Nautilus Biotechnology and Abcam announced a strategic partnership to enhance proteomic analysis through the development of affinity binding reagents. This collaboration will leverage Abcam's monoclonal antibody technologies to support Nautilus in reagent R&D and establish a long-term supply relationship. Initially focused on affinity reagents, it aims for large-scale manufacturing for commercialization. Both companies emphasize the partnership's potential to improve drug and diagnostic tool development, catering to the growing importance of proteomic data.
Nautilus Biotechnology (NASDAQ: NAUT) has announced a strategic partnership with Abcam to enhance its reagent development capabilities. This collaboration aims to accelerate R&D by utilizing Abcam's advanced monoclonal antibody technologies. The focus will be on developing affinity binding reagents for Nautilus' proteomic analysis system, followed by large-scale manufacturing and commercialization. This partnership is seen as a significant step toward improving drug and diagnostic tool development, enhancing the overall efficacy of Nautilus’ protein analysis platform.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its third-quarter financial results for 2021, highlighting significant business developments and financial metrics. The company initiated a strategic partnership with Abcam to enhance protein detection and signed two new research collaborations with a global pharmaceutical company and UT MD Anderson Cancer Center. Financially, Nautilus recorded an operating expense of $14.6 million, a 262% increase from the previous year, and a net loss of $14.5 million. However, cash reserves stood strong at $374 million as of September 30, 2021.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will report its financial results for Q3 2021 on November 2, 2021. Prior to the market open, the company will hold a webcast at 5:30 a.m. PT / 8:30 a.m. ET to discuss its results and business developments. Nautilus is focused on a single-molecule protein analysis platform aimed at revolutionizing proteomics and enhancing human health and medicine.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will participate virtually at the Morgan Stanley Global Healthcare Conference on September 15, 2021, at 1:15 p.m. ET. The event will feature a presentation detailing Nautilus' innovative single-molecule protein analysis platform that quantifies the human proteome. Attendees can access a live and archived webcast through Nautilus' website. The company aims to enhance basic science research and improve therapeutic development through its advanced proteomics technology.
Nautilus Biotechnology reported its second quarter 2021 financial results, revealing significant developments since becoming publicly traded on June 10, 2021, with gross proceeds of approximately $345.5 million. The company's operating expenses surged by 215% to $10.7 million, compared to $3.4 million in Q2 2020, primarily due to increased headcount and public company costs. The net loss for the quarter was $10.7 million, up from $3.4 million year-over-year. Nautilus aims for platform commercialization by late 2023 and bolstered its team with key appointments.
Nautilus Biotechnology has appointed Karl Voss, Ph.D., as the new Vice President of Life Sciences Research and Development. With over 20 years of experience, Dr. Voss previously worked at Pacific Biosciences, where he significantly contributed to the advancement of single-molecule DNA sequencing. His expertise is expected to enhance Nautilus’ mission to transform understanding in human biology through their innovative protein analysis platform, which aims to quantify over 95% of the proteome. This appointment follows Nautilus' recent public trading debut.
FAQ
What is the current stock price of Nautilus Biotechnology (NAUT)?
What is the market cap of Nautilus Biotechnology (NAUT)?
